Background: In Mongolia, 80.1% of women of reproductive age suffer from vitamin D deficiency. This deficiency is associated with an increased risk of rickets, osteomalacia, weakened immunity, hypertension, diabetes, and infectious diseases.Currently, Mongolia imports vitamin D-containing pharmaceutical products, and no research has been conducted on the pharmaceutical formulation technology of orally administered vitamin D3 products. Vitamin D3 is highly sensitive to environmental factors such as ultraviolet (UV) light, oxidation, and temperature changes, leading to its degradation. Therefore, improving its stability in pharmaceutical formulations is essential. The need for a stable vitamin D3-containing pharmaceutical product serves as the basis for this study. Aim: To develop a tablet formulation containing cholecalciferol. Materials and Methods: The study was conducted in collaboration with the Department of Pharmaceutical Technology at the School of Pharmacy, Mongolian National University of Medical Sciences, and the drug development laboratory of “Monos Pharm” LLC. To enhance the stability and technological properties of cholecalciferol, a spray-drying technique was used to prepare five different emulsions containing various excipients. Microencapsulation was performed to improve stability, and the most suitable formulation and technological parameters were selected. From the microencapsulated cholecalciferol, tablet formulations were developed using both direct compression and wet granulation techniques. The quality parameters of the tablets were assessed according to the United States Pharmacopeia (USP), and the optimal technological process for tablet production was determined. Results: A stable microencapsulated cholecalciferol formulation was successfully developed, and suitable excipients were selected. The quantitative content of cholecalciferol was determined to be 1791 IU, with variations ranging from -8.38% to -11.38%. Conclusion The study identified appropriate excipients and technological parameters for obtaining microencapsulated cholecalciferol. Additionally, the optimal formulation and processing parameters for developing a tablet dosage form containing microencapsulated cholecalciferol were established.